India Exchange Filings

Orchid Pharma Q2 FY27 Results and Board Meeting Highlights

Orchid Pharma Ltd approves Q2 FY27 results, reporting consolidated net profit of ₹28.59 crore

  • Consolidated revenue was ₹341.27 crore, up 12.2% sequentially and 14.4% year on year; estimated EBITDA margin was 7.1%.
  • Net profit compared with ₹3.22 crore in Q1 FY27 and a ₹0.90 crore loss in Q2 FY26.
  • Standalone revenue was ₹341.27 crore and net profit ₹36.76 crore, with an estimated 6.8% EBITDA margin; auditors issued unmodified review conclusions, with no exceptional item reported.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.